GO
Loading...

Gilead Sciences Inc

More

  • Why one VC is investing, despite seeing a bubble Tuesday, 3 Feb 2015 | 11:07 AM ET

    Joe Horowitz has been in venture capital for three decades, so he knows how to spot a bubble. Too many billion-dollar start-ups is a big sign.

  • These stocks will benefit from the stronger dollar Tuesday, 3 Feb 2015 | 8:05 AM ET
    Traders work the floor of the New York Stock Exchange.

    Analysts are eyeing earnings from consumer firms and small-cap stocks, which actually benefit from a stronger U.S. dollar.

  • Can recent oil gains continue to power stocks? Tuesday, 3 Feb 2015 | 6:02 AM ET
    Traders work the floor of the New York Stock Exchange.

    News of a debt settlement proposal between Greece and the European Union also eased U.S. investor worries on Monday, putting earnings back in focus.

  • WASHINGTON, Feb 2- The Obama administration said on Monday it would seek authority to negotiate prices for high-cost drugs under the government's Medicare Part D program, which offers private drug coverage for senior citizens and the disabled. But the plan would require the administration to get a green light from Congress, where Republicans who control the...

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • WASHINGTON, Feb 2- The Obama administration said on Monday it would seek authority to negotiate pricing for high-cost drugs under the federal government's Medicare Part D program, which offers private insurance drug coverage for senior citizens and the disabled. President Barack Obama's new $3.99 trillion budget for fiscal-year 2016 proposes allowing...

  • FINAL TRADES JAN. 30, 2015 Friday, 30 Jan 2015 | 2:14 PM ET
  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • Early movers: YHOO, FL, TYC, XRX, TSN & more Friday, 30 Jan 2015 | 7:57 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • UPDATE 1-U.S. FDA approves Bristol-Myers, J&J HIV pills Thursday, 29 Jan 2015 | 6:35 PM ET

    Jan 29- The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors- one made by Bristol-Myers Squibb Co and the other by Johnson& Johnson- both with a boosting agent produced by Gilead Sciences Inc.. Bristol-Myers said its drug, Evotaz, is a once-daily pill containing Reyataz, also known as atazanavir, a...

  • U.S. FDA approves Bristol-Myers' HIV drug Thursday, 29 Jan 2015 | 5:44 PM ET

    Jan 29- The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday. The new drug combines Reyataz, also known as atazanavir, a Bristol-Myers' protease inhibitor, with cobicistat, a boosting agent produced by Gilead Sciences Inc..

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Lightning Round: I prefer this to Alibaba Tuesday, 20 Jan 2015 | 6:56 PM ET
    A woman walking past Alibaba signage in Hangzhou, China.

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Oil, dollar to determine earnings winners, losers Wednesday, 14 Jan 2015 | 10:53 AM ET
    A CSX employee walks on a locomotive while on a siding at Worthville, Ky., Oct. 11, 2013.

    The plunge in oil and the strong dollar are the lead factors in determining stocks to buy or short as the fourth quarter earnings reports come out.

  • Navellier’s crunching finds growth for cheap Wednesday, 14 Jan 2015 | 6:00 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...